Prognosis and chemotherapy efficacy in small-tumor breast cancer with different immune subtypes: a SEER-based study
In addition to T1cN2+ stage or HR-HER2- subtype, this study identified T1mi/a-bN1 HR-HER2+ subgroup as a high-risk type in small-tumor breast cancer. And small-tumor breast cancer patients do not usually benefit from AC. AC may not be recommended for certain subgroups, such as patients with pT1mi/a-bN0-1 HR+HER2- or pT1mi/a-bN0 HR-HER2-/HR+HER2+ can be exempted from chemotherapy.
Authors
- Xiao Xi Huang
- Bi Lian Zheng
- Kun Zhang
- Yi Peng
- Xiu Rong Chi
- Hua Le Zhang
- Hong Mei Wang
- Yue Hui Zhou
- Gu Bin Lin
Institutions
- Fujian Medical University (CN)
- Fuzhou Maternity and Child Health Care Hospital (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tcr-2025-1349
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00